Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine if the use of losartan, an angiotensin II receptor
blocker, can attenuate left ventricular hypertrophy, independent of its antihypertensive
effects, in patients with near end stage chronic kidney disease (CKD) who have an
arteriovenous fistula created.
Secondary outcomes include the impact of the medication on BNP and hyperkalaemia